{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:03:14Z","timestamp":1762527794781,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ajoc.2021.101027","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T12:55:50Z","timestamp":1612616150000},"page":"101027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Beh\u00e7et's disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Ahmad","family":"Al-Moujahed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doan Luong","family":"Hien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-4330","authenticated-orcid":false,"given":"Amir","family":"Akhavanrezayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon Huy","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Than Trong","family":"Tuong Ngoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy Luong","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7igdem","family":"Ya\u015far","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-3827","authenticated-orcid":false,"given":"Sherin","family":"Lajevardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy Vu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et's disease: new insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Ka\u00e7maz","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-014-8425-z","article-title":"Ocular involvement of Beh\u00e7et\u2019s syndrome: a comprehensive review","volume":"49","author":"Ozyazgan","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ajoc.2021.101027_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/197675","article-title":"Ischemic retinal vasculitis and its management","volume":"2014","author":"Talat","year":"2014","journal-title":"Journal of ophthalmology"},{"issue":"4","key":"10.1016\/j.ajoc.2021.101027_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/0974-9233.58423","article-title":"Differential diagnosis of retinal vasculitis","volume":"16","author":"El-Asrar","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/eye.1996.71","article-title":"Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis","volume":"10","author":"Palmer","year":"1996","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00055735-200312000-00015","article-title":"Retinal vasculitis","volume":"14","author":"Walton","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib9","first-page":"808","article-title":"Update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018"},{"issue":"1","key":"10.1016\/j.ajoc.2021.101027_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","article-title":"Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Beh\u00e7et disease: a 2-year follow-up study","volume":"25","author":"Keino","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"121","key":"10.1016\/j.ajoc.2021.101027_bib11","first-page":"S137","article-title":"Induction of ocular Beh\u00e7et's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years","volume":"37","author":"Sfikakis","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/ceo.13511","article-title":"New therapies in development for the management of non\u2010infectious uveitis: a review","volume":"47","author":"Hassan","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2021.101027_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajoc.2021.101027_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1756-185X.13095","article-title":"High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study","volume":"20","author":"Mohammadi","year":"2017","journal-title":"International journal of rheumatic diseases"},{"issue":"5","key":"10.1016\/j.ajoc.2021.101027_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ajoc.2021.101027_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.sjopt.2016.12.004","article-title":"Successful treatment of Beh\u00e7et\u2019s uveitis with Tocilizumab","volume":"31","author":"Alokaily","year":"2017","journal-title":"Saudi Journal of Ophthalmology"},{"issue":"6 Suppl 102","key":"10.1016\/j.ajoc.2021.101027_bib17","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.ajoc.2021.101027_bib18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.ajoc.2021.101027_bib19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Behcet's disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.ajoc.2021.101027_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajoc.2021.101027_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.ajoc.2021.101027_bib23","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"issue":"suppl 2","key":"10.1016\/j.ajoc.2021.101027_bib24","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet's disease: a new target for anti-tumour necrosis factor treatment","volume":"61","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ajoc.2021.101027_bib25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajoc.2021.101027_bib26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2021.101027_bib27","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/765380","article-title":"High dose infliximab in the treatment of refractory uveitis: does dose matter?","volume":"2012","author":"Sukumaran","year":"2012","journal-title":"ISRN rheumatology"},{"key":"10.1016\/j.ajoc.2021.101027_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Group","year":"1975","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib29","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajoc.2021.101027_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.ajoc.2021.101027_bib31","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin\u2010induced flushing","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"7-8","key":"10.1016\/j.ajoc.2021.101027_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/02713680600760501","article-title":"Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration","volume":"31","author":"Barakat","year":"2006","journal-title":"Curr Eye Res"},{"issue":"12","key":"10.1016\/j.ajoc.2021.101027_bib33","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/bjo.2004.046607","article-title":"Effect of niacin on the choroidal circulation of patients with age related macular degeneration","volume":"88","author":"Metelitsina","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archopht.1976.03910030475008","article-title":"Sarcoidosis with optic nerve and retinal involvement","volume":"94","author":"Gass","year":"1976","journal-title":"Archives of ophthalmology (Chicago, Ill : 1960"},{"issue":"2","key":"10.1016\/j.ajoc.2021.101027_bib35","first-page":"164","article-title":"A clinical and histopathological review of intermediate uveitis (\"pars planitis\")","volume":"64","author":"Eichenbaum","year":"1988","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.ajoc.2021.101027_bib36","doi-asserted-by":"crossref","first-page":"197675","DOI":"10.1155\/2014\/197675","article-title":"Ischemic retinal vasculitis and its management","volume":"2014","author":"Talat","year":"2014","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2021.101027_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2990.2003.00499.x","article-title":"The pathology and pathogenesis of retinal vasculitis","volume":"29","author":"Hughes","year":"2003","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"24","key":"10.1016\/j.ajoc.2021.101027_bib38","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/S0042-6989(96)00328-8","article-title":"Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid","volume":"37","author":"Rosenbaum","year":"1997","journal-title":"Vis Res"},{"issue":"2","key":"10.1016\/j.ajoc.2021.101027_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1167\/iovs.03-0557","article-title":"Supplemental oxygen improves diabetic macular edema: a pilot study","volume":"45","author":"Nguyen","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajoc.2021.101027_bib40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/jamaophthalmol.2016.1028","article-title":"Potentially reversible effect of niacin therapy on edema from retinal vein occlusion","volume":"134","author":"Rahimy","year":"2016","journal-title":"JAMA ophthalmology"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib41","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00417-017-3606-0","article-title":"Effect of oral niacin on central retinal vein occlusion","volume":"255","author":"Gaynon","year":"2017","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2021.101027_bib42","first-page":"36","article-title":"Nicotinic acid treatment for retinal vein occlusion","volume":"2","author":"Abrishami","year":"2014","journal-title":"Patient Saf Qual Improv"},{"issue":"1","key":"10.1016\/j.ajoc.2021.101027_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-012-0449-3","article-title":"Pathophysiology and treatment of diabetic retinopathy","volume":"50","author":"Bandello","year":"2013","journal-title":"Acta Diabetol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib44","first-page":"362","article-title":"Diabetes and retinal vascular dysfunction","volume":"9","author":"Shin","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"7","key":"10.1016\/j.ajoc.2021.101027_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132644","article-title":"Experimental branch retinal vein occlusion induces upstream pericyte loss and vascular destabilization","volume":"10","author":"Dominguez","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ajoc.2021.101027_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OPTH.S7631","article-title":"Retinal vein occlusion: pathophysiology and treatment options","volume":"4","author":"Karia","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajoc.2021.101027_bib47","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/S0161-6420(99)90483-9","article-title":"Pathophysiology and hemodynamics of branch retinal vein occlusion","volume":"106","author":"Christoffersen","year":"1999","journal-title":"Ophthalmology"},{"issue":"Pt 1","key":"10.1016\/j.ajoc.2021.101027_bib48","first-page":"178","article-title":"Collateral vessels in branch retinal vein occlusion","volume":"102","author":"Pieris","year":"1982","journal-title":"Trans Ophthalmol Soc U K"},{"issue":"7","key":"10.1016\/j.ajoc.2021.101027_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215790","article-title":"Exploring the relationship between collaterals and vessel density in retinal vein occlusions using optical coherence tomography angiography","volume":"14","author":"Lee","year":"2019","journal-title":"PloS One"},{"article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","year":"2005","series-title":"Seminars in Arthritis and Rheumatism","key":"10.1016\/j.ajoc.2021.101027_bib50"},{"issue":"6","key":"10.1016\/j.ajoc.2021.101027_bib51","first-page":"285","article-title":"Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Beh\u00e7et\u2019disease","volume":"90","author":"Baneros-Rojas","year":"2015","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2021.101027_bib52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4103\/ijo.IJO_782_17","article-title":"Transient reversal of macular ischemia with intravitreal steroid implant injection in a case of radiation maculopathy","volume":"66","author":"Verma","year":"2018","journal-title":"Indian J Ophthalmol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993621000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993621000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:58:13Z","timestamp":1762527493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993621000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":52,"alternative-id":["S2451993621000189"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2021.101027","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2021.101027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101027"}}